Market revenue in 2023 | USD 1,014.7 million |
Market revenue in 2030 | USD 1,480.1 million |
Growth rate | 5.5% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.71% in 2023. Horizon Databook has segmented the Japan rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Japan rheumatoid arthritis therapeutics market has seen a significant development with the approval of METOJECT Subcutaneous Injection Syringe (methotrexate) for treating RA. This approval, announced in September 2022 by Eisai Co., Ltd. and Nippon Medac Co., Ltd., marked the introduction of the first self-administrable methotrexate subcutaneous injection formulation for RA in Japan.
The approval of METOJECT offers a new treatment option for RA patients in Japan and addresses the need for convenient & effective self-administration methods. This development is expected to positively impact the RA therapeutics market in Japan by providing patients with a more accessible and user friendly treatment option.
Furthermore, the collaboration between Eisai and Nippon Medac, facilitated by a license agreement signed in 2019, highlights the importance of partnerships and collaborations in driving innovation & expanding treatment options in the RA therapeutics market.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account